Surrozen initiated with a Buy at H.C. Wainwright

H.C. Wainwright analyst Matthew Caufield initiated coverage of Surrozen (SRZN) with a Buy rating and $32 price target Surrozen is advancing novel therapies based on the selective modulation of the Wingless-related integration site pathway, the analyst tells investors in a research note. The firm says the company is developing tissue-specific antibodies that could leverage the body’s biological repair and regeneration mechanisms.